

October 19th , 2023

Please find attached IRB approval of our study entitled “**Comparison of Fungal Vs Bacterial Infections in the Medical Intensive Liver Unit: Cause or Corollary for High Mortality?**”. This study was performed as a part of our overarching study of sepsis within our medical intensive liver unit, and as such was approved as such by our institutional review board (IRB).

Sincerely,



Sarah Khan, MD



September 20, 2022

Christina Lindenmeyer, M.D.

RE: IRB# 22-721: Sepsis in the MILU: A Comparison of Risk Factors and Outcomes of Infection With Multi-Drug Resistant Organisms vs Non-Multi Drug Resistance Organisms Peri-Transplant

Dear Dr. Lindenmeyer:

The submission on 9/3/2022 of Protocol 9/3/22 and Summary of Changes was **approved** under expedited review on 9/20/2022.

Data collection end date corrected to match initial application- 12/31/22.

A waiver of Informed Consent and waiver of HIPAA authorization is approved to allow access to PHI by the research team however, sharing or releasing identifiable data to anyone other than the study team is not permitted without additional IRB approval.

Please note that human subjects research at Cleveland Clinic has been impacted by COVID-19. The study team is responsible for compliance with the enterprise-wide restrictions related to research. This information is available on the Intranet, including the Center for Clinical Research homepage.

If you have any questions or concerns, you may contact the IRB Office at [216-444-2924](tel:216-444-2924) or email IRB@ccf.org.

Sincerely,

A handwritten signature in black ink that reads "Bridget Howard".

Bridget Howard, Esq., CIP
Executive Director, IRB and Human Research Protections

BH/sls

This letter is available online under the Correspondence tab.